Journal
VACCINE
Volume 36, Issue 5, Pages 716-722Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2017.12.025
Keywords
CRISPR/Cas9; HVT; Cre-loxP; Recombinant vaccine
Categories
Funding
- Biotechnology and Biological Sciences Research Council (BBSRC) [BB/P016472/1, BB/L014262/1]
- Royal Society [IC 160046]
- BBSRC [BB/M027481/1, BBS/E/I/00007039, BBS/E/I/00007037, BB/R007896/1, BBS/E/I/00007032, BB/R012865/1, BB/L014262/1] Funding Source: UKRI
- Biotechnology and Biological Sciences Research Council [BBS/OS/NW/000007, BBS/E/I/00007032, BB/R012865/1, BBS/E/I/00007037, BB/M027481/1, BBS/E/I/00007039, BB/L014262/1, BB/R007896/1] Funding Source: researchfish
Ask authors/readers for more resources
Herpesvirus of turkeys (HVT) has been successfully used as live vaccine against Marek's disease (MD) worldwide for more than 40 years either alone or in combination with other serotypes. HVT is also widely used as a vector platform for generation of recombinant vaccines against a number of avian diseases such as infectious bursal disease (IBD), Newcastle disease (ND) and avian influenza (AI) using conventional recombination methods or recombineering tools on cloned viral genomes. In the present study, we describe the application of CRISPR/Cas9-based genome editing as a rapid and efficient method of generating HVT recombinants expressing VP2 protein of IBDV. This approach offers an efficient method to introduce other viral antigens into the HVT genome for rapid development of recombinant vaccines. (C) 2018 The Pirbright Institute. Published by Elsevier Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
